Friday, May 05, 2017 2:15:58 PM
By Lee Jackson May 5, 2017 8:20 am EDT
One segment in the markets that has been dogged with issues for almost two years is the big pharmaceuticals, as numerous factors have kept the lid on share prices and, in some cases, kept the headlines right in investors’ faces. The biggest issue is the seemingly constant and somewhat shrill rhetoric from attention-seeking politicians over drug prices. While that may play well with constituents, it can be difficult for companies trying to deliver for shareholders.
In a new research report, the outstanding team at JPMorgan make the case that the best place for investors to look when considering large cap drug stocks is companies that have strong new product cycles already in motion. They also focus on stocks with attractive top-line and margin expansion potential. Three make the grade, and are all rated Overweight.
Bristol-Myers Squibb
This top company remains a favorite at Jefferies and ranks as the fourth top global pick. Bristol-Myers Squibb Co. (NYSE: BMY) is a global pharmaceutical company focused on discovering, developing, licensing and marketing chemically synthesized drugs or small molecules and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV), oncology, neuroscience, immunoscience and cardiovascular.
The company recently announced that Biogen will pay $300 million upfront to Bristol-Myers to license a palsy drug with a $2 billion market opportunity and the potential to use that to treat Alzheimer’s. The company will pay a total of $410 million in milestone payments and a tiered double-digit royalty to license a drug known only as BMS-986168. The drug just completed Phase 1 testing in progressive supranuclear palsy.
The company reported first-quarter profit and revenue that exceeded Wall Street expectations. The results included a 60% increase in global revenues for cancer drug Opdivo, compared with the year-earlier period,
Shareholders receive a 2.83% dividend. JPMorgan has a $66 price objective, and the consensus target price is $56.33. The shares closed on Thursday at $55.19.
(other 2 stocks omitted)
_______________________________________________________
http://247wallst.com/healthcare-business/2017/05/05/jpmorgan-has-3-top-pick-large-cap-pharmaceuticals-to-buy-for-the-rest-of-2017/
BMY
Recent BMY News
- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis • Business Wire • 09/18/2024 10:59:00 AM
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma • Business Wire • 09/15/2024 12:55:00 PM
- Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 • Business Wire • 09/12/2024 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/10/2024 09:45:00 PM
- Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms • Business Wire • 09/09/2024 10:59:00 AM
- Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research • Business Wire • 09/06/2024 11:00:00 AM
- Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) • Business Wire • 09/01/2024 07:33:00 AM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 08/27/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024 • Business Wire • 08/26/2024 10:59:00 AM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma • Business Wire • 08/21/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma • Business Wire • 08/19/2024 10:59:00 AM
- Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots • IH Market News • 07/30/2024 10:00:51 AM
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 • Business Wire • 07/26/2024 10:59:00 AM
- U.S. Index Futures Point to Higher Open, Oil Prices Down • IH Market News • 07/26/2024 10:08:50 AM
- Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates • IH Market News • 07/26/2024 09:57:38 AM
- Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma • Business Wire • 07/19/2024 10:59:00 AM
- Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day • Business Wire • 07/08/2024 10:59:00 AM
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 06/21/2024 11:30:00 PM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab • Business Wire • 06/21/2024 10:59:00 AM
- Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024 • Business Wire • 06/20/2024 10:59:00 AM
- Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors • Business Wire • 06/18/2024 08:16:00 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 06/18/2024 10:59:00 AM
- U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors • Business Wire • 06/13/2024 08:46:00 PM
- Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial • Business Wire • 06/04/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM